{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:15:34Z","timestamp":1791288934189,"version":"4.3.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007458","name":"Qatar Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007458","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jhep.2020.09.013","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T22:20:26Z","timestamp":1600726826000},"page":"535-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["A global investment framework for the elimination of hepatitis B"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9269-6249","authenticated-orcid":false,"given":"Jessica","family":"Howell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1998-5722","authenticated-orcid":false,"given":"Alisa","family":"Pedrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-7346","authenticated-orcid":false,"given":"Sophia E.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9213-0798","authenticated-orcid":false,"given":"Nick","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Aufegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-5983","authenticated-orcid":false,"given":"Rifat","family":"Atun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Baptista-Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"Hirnschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"\u2018t Hoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon J.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-2299","authenticated-orcid":false,"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesi","family":"Olufunmilayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manik","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette H.","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8218-192X","authenticated-orcid":false,"given":"Mark","family":"Thursz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-3266","authenticated-orcid":false,"given":"Margaret","family":"Hellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhep.2020.09.013_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10049","key":"10.1016\/j.jhep.2020.09.013_bib3","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jhep.2020.09.013_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2020.09.013_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2020.09.013_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2020.09.013_bib8","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10100","key":"10.1016\/j.jhep.2020.09.013_bib9","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"issue":"10100","key":"10.1016\/j.jhep.2020.09.013_bib10","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0140-6736(17)32130-X","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jhep.2020.09.013_bib11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/heapol\/czy018","article-title":"The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up","volume":"33","author":"Hecht","year":"2018","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.jhep.2020.09.013_bib12","series-title":"Eliminating Viral Hepatitis: The Investment Case","author":"Pedrana","year":"2019"},{"key":"10.1016\/j.jhep.2020.09.013_bib13","series-title":"Global Health Sector Strategy on Viral Hepatitis 2016-2021","year":"2016"},{"issue":"2","key":"10.1016\/j.jhep.2020.09.013_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2020.09.013_bib15","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","article-title":"Requirements for global elimination of hepatitis B: a modelling study","volume":"16","author":"Nayagam","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2020.09.013_bib16","series-title":"Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2019. Accountability for the Global Helath Sector Strategies, 2016-2021","year":"2019"},{"issue":"10125","key":"10.1016\/j.jhep.2020.09.013_bib17","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S0140-6736(15)60097-6","article-title":"Disease control priorities, 3rd edition: improving health and reducing poverty","volume":"391","author":"Jamison","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jhep.2020.09.013_bib18","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2020.09.013_bib19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2020.09.013_bib20","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S2468-1253(20)30010-8","article-title":"Global hepatitis C elimination: an investment case","volume":"5","author":"Pedrana","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.09.013_bib22","series-title":"The Secretary-General's Strategy for Financing the 2030 Agenda for Sustainable Devlopment (2018-2021)","year":"2018"},{"issue":"9858","key":"10.1016\/j.jhep.2020.09.013_bib23","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/S0140-6736(12)61460-3","article-title":"Innovative financing for health: what is truly innovative?","volume":"380","author":"Atun","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jhep.2020.09.013_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhepr.2019.04.002","article-title":"Global progress on the elimination of viral hepatitis as a major public health threat: an analysis of WHO Member State responses 2017","volume":"1","author":"Smith","year":"2019","journal-title":"JHEP Rep"},{"issue":"7","key":"10.1016\/j.jhep.2020.09.013_bib25","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1016\/S2214-109X(17)30198-5","article-title":"Innovative financing instruments for global health 2002-15: a systematic analysis","volume":"5","author":"Atun","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"10","key":"10.1016\/j.jhep.2020.09.013_bib26","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/liv.14222","article-title":"Innovative strategies for the elimination of viral hepatitis at a national level: a country case series","volume":"39","author":"Schroeder","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.09.013_bib27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2471\/BLT.09.074419","article-title":"Taskforce on innovative international financing for health systems: what next?","volume":"88","author":"McCoy","year":"2010","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jhep.2020.09.013_bib29","series-title":"The Secretary-General's Strategy for Financing the 2030 Agenda for Sustainable Devlopment (2018 - 2021)","year":"2018"},{"key":"10.1016\/j.jhep.2020.09.013_bib30","series-title":"Transforming Our World: The 2030 Agenda for Sustainable Development","year":"2015"},{"issue":"9","key":"10.1016\/j.jhep.2020.09.013_bib31","doi-asserted-by":"crossref","first-page":"e875","DOI":"10.1016\/S2214-109X(17)30263-2","article-title":"Financing transformative health systems towards achievement of the health sustainable development goals: a model for projected resource needs in 67 low-income and middle-income countries","volume":"5","author":"Stenberg","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jhep.2020.09.013_bib32","series-title":"Monitoring Progress Towards Universal Health Coverage at Country and Global Levels: Framework, Measures and Targets","year":"2014"},{"issue":"4","key":"10.1016\/j.jhep.2020.09.013_bib85","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/heapol\/czy018","article-title":"The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up","volume":"33","author":"Hecht","year":"2018","journal-title":"Health Policy Plan"},{"issue":"S1","key":"10.1016\/j.jhep.2020.09.013_bib36","first-page":"p132","article-title":"Investment case for a comprehensive package of interventions against hepatitis B in China","volume":"64","author":"Nayagam","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.09.013_bib86","series-title":"Strategic Plan Against Viral Hepatitis in Senegal (2019-2023): Policy Brief","year":"2019"},{"issue":"8","key":"10.1016\/j.jhep.2020.09.013_bib33","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2214-109X(16)30101-2","article-title":"Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in the Gambia: an economic modelling analysis","volume":"4","author":"Nayagam","year":"2016","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.jhep.2020.09.013_bib60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/jgh.14457","article-title":"Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: where are we now and barriers to meeting World Health Organization targets by 2030","volume":"34","author":"Howell","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.09.013_bib87","series-title":"Third National Hepatitis B Strategy","year":"2018"},{"issue":"6","key":"10.1016\/j.jhep.2020.09.013_bib59","doi-asserted-by":"crossref","first-page":"e596","DOI":"10.1016\/S2214-109X(18)30233-X","article-title":"Game changing: hepatitis B vaccine in a controlled temperature chain","volume":"6","author":"Patel","year":"2018","journal-title":"Lancet Glob Health"},{"issue":"4","key":"10.1016\/j.jhep.2020.09.013_bib69","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1128\/JCM.02980-14","article-title":"Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa","volume":"53","author":"Njai","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2020.09.013_bib34","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1186\/s12879-017-2778-x","article-title":"Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries","volume":"17","author":"Nayagam","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.jhep.2020.09.013_bib35","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1186\/s12889-019-7095-4","article-title":"Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa","volume":"19","author":"Mokaya","year":"2019","journal-title":"BMC Public Health"},{"issue":"9","key":"10.1016\/j.jhep.2020.09.013_bib37","doi-asserted-by":"crossref","first-page":"e1180","DOI":"10.1016\/S2214-109X(19)30272-4","article-title":"Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30","volume":"7","author":"Tordrup","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"5","key":"10.1016\/j.jhep.2020.09.013_bib38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/jvh.13252","article-title":"Enhancing the hepatitis B care cascade in Australia: a cost-effectiveness model","volume":"27","author":"Xiao","year":"2019","journal-title":"J\u00a0Viral Hep"},{"issue":"6","key":"10.1016\/j.jhep.2020.09.013_bib56","doi-asserted-by":"crossref","first-page":"e659","DOI":"10.1016\/S2214-109X(18)30219-5","article-title":"Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study","volume":"6","author":"Scott","year":"2018","journal-title":"Lancet Glob Health"},{"issue":"4","key":"10.1016\/j.jhep.2020.09.013_bib42","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ije\/dyz037","article-title":"Integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis is highly effective and cost-effective: an economic evaluation","volume":"48","author":"Zhang","year":"2019","journal-title":"Int J Epidemiology"},{"key":"10.1016\/j.jhep.2020.09.013_bib89","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12962-018-0088-9","article-title":"Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea","volume":"16","author":"Lee","year":"2018","journal-title":"Cost Eff Resour Alloc"},{"issue":"11","key":"10.1016\/j.jhep.2020.09.013_bib90","doi-asserted-by":"crossref","first-page":"e0207037","DOI":"10.1371\/journal.pone.0207037","article-title":"Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country","volume":"13","author":"Suijkerbuijk","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.jhep.2020.09.013_bib39","series-title":"Centre for Disease Analysis: Dalberg Analysis; in: Importance of Hepatitis B and C Control and Elimination, World Hepatitis Alliance","year":"2017"},{"issue":"8","key":"10.1016\/j.jhep.2020.09.013_bib40","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1016\/S2214-109X(16)30130-9","article-title":"Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in the Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study","volume":"4","author":"Lemoine","year":"2016","journal-title":"Lancet Glob Health"},{"issue":"4","key":"10.1016\/j.jhep.2020.09.013_bib41","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jhep.2018.05.024","article-title":"Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa","volume":"69","author":"Shimakawa","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.09.013_bib43","series-title":"Innovative Financing into Hepatitis B and C Prevention and Treatment in Low and Middle Income Countries","year":"2016"},{"issue":"3","key":"10.1016\/j.jhep.2020.09.013_bib44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2020.06.008","article-title":"Strengthening vaccine confidence during the COVID-19 pandemic: a new opportunity for global hepatitis B virus elimination","volume":"73","author":"Lazarus","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.09.013_bib45","series-title":"Step Up the Fight. Investment Case Summary","year":"2019"},{"issue":"2","key":"10.1016\/j.jhep.2020.09.013_bib47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S2468-1253(16)30161-3","article-title":"Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium","volume":"2","author":"Yang","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10159","key":"10.1016\/j.jhep.2020.09.013_bib48","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.09.013_bib49","series-title":"Monitoring and Evaluation for Viral Hepatitis B and C: Recommended Indicators and Framework","year":"2016"},{"key":"10.1016\/j.jhep.2020.09.013_bib91","unstructured":"World Health Organisation. Standards and Tools to Strengthen Country Monitoring and Evaluation https:\/\/www.who.int\/ 2018. Available at: https:\/\/www.who.int\/healthinfo\/topics_standards_tools\/en\/. [Accessed 4 April 2020]."},{"issue":"5","key":"10.1016\/j.jhep.2020.09.013_bib50","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination survey 2003 to 2010","volume":"160","author":"Denniston","year":"2014","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jhep.2020.09.013_bib51","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S2468-1253(16)30031-0","article-title":"Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments","volume":"1","author":"Wait","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2020.09.013_bib52","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12939-017-0637-4","article-title":"More than a virus: a qualitative study of the social implications of hepatitis B infection in China","volume":"16","author":"Wallace","year":"2017","journal-title":"Int J Equity Health"},{"issue":"6","key":"10.1016\/j.jhep.2020.09.013_bib53","doi-asserted-by":"crossref","first-page":"e35566","DOI":"10.5812\/hepatmon.35566","article-title":"Hepatitis B-related concerns and anxieties among people with chronic hepatitis B in Australia","volume":"16","author":"Hajarizadeh","year":"2016","journal-title":"Hepat Mon"},{"key":"10.1016\/j.jhep.2020.09.013_bib54","series-title":"Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection","year":"2015"},{"key":"10.1016\/j.jhep.2020.09.013_bib55","series-title":"WHO Guideline on the Use of Safety-Engineered Syringes for Intramuscular, Intradermal and Subcutaneous Injections in Health Care Settings","year":"2016"},{"issue":"1","key":"10.1016\/j.jhep.2020.09.013_bib57","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.vaccine.2017.11.027","article-title":"Status and progress of hepatitis B control through vaccination in the South-East Asia region, 1992-2015","volume":"36","author":"Childs","year":"2018","journal-title":"Vaccine"},{"issue":"9579","key":"10.1016\/j.jhep.2020.09.013_bib58","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/S0140-6736(07)60325-0","article-title":"Achieving child survival goals: potential contribution of community health workers","volume":"369","author":"Haines","year":"2007","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.jhep.2020.09.013_bib61","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"NEJM"},{"issue":"5","key":"10.1016\/j.jhep.2020.09.013_bib62","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/ije\/dyy077","article-title":"Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China","volume":"47","author":"Cui","year":"2018","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jhep.2020.09.013_bib63","series-title":"Regional Framework for the Triple Elimination of Mother-to-Child Transmission of HIV, Hepatitis B and Syphilis in Asia and the Pacific, 2018-2030","year":"2018"},{"issue":"3","key":"10.1016\/j.jhep.2020.09.013_bib64","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/COH.0000000000000370","article-title":"Diagnosis of viral hepatitis","volume":"12","author":"Easterbrook","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jhep.2020.09.013_bib65","series-title":"World Health Organization Model List of Essential In\u00a0Vitro Diagnostics","author":"World Health Organization","year":"2018"},{"issue":"1","key":"10.1016\/j.jhep.2020.09.013_bib66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection","volume":"47","author":"Mak","year":"2018","journal-title":"Alim Pharm Ther"},{"issue":"11","key":"10.1016\/j.jhep.2020.09.013_bib67","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/jvh.12931","article-title":"Detection of hepatitis B virus DNA among chronic and potential occult HBV patients in resource-limited settings by Loop-Mediated Isothermal Amplification assay","volume":"25","author":"Akram","year":"2018","journal-title":"J\u00a0Viral Hep"},{"issue":"S812","key":"10.1016\/j.jhep.2020.09.013_bib68","article-title":"Validation of a novel rapid point-of-care alt test in patients with viral hepatitis (PO 2819)","volume":"73","author":"Howell","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2020.09.013_bib70","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1186\/s12879-017-2775-0","article-title":"The future of viral hepatitis testing: innovations in testing technologies and approaches","volume":"17","author":"Peeling","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.jhep.2020.09.013_bib71","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S2055-6640(20)30484-2","article-title":"Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries","volume":"1","author":"Hill","year":"2015","journal-title":"J\u00a0Virus Eradication"},{"issue":"1","key":"10.1016\/j.jhep.2020.09.013_bib72","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12916-018-1162-z","article-title":"Pathways to ensure universal and affordable access to hepatitis C treatment","volume":"16","author":"Douglass","year":"2018","journal-title":"BMC Med"},{"issue":"28","key":"10.1016\/j.jhep.2020.09.013_bib73","doi-asserted-by":"crossref","first-page":"773","DOI":"10.15585\/mmwr.mm6728a2","article-title":"Access to treatment for hepatitis B virus infection - worldwide, 2016","volume":"67","author":"Hutin","year":"2018","journal-title":"MMWR Morbidity Mortality Weekly Rep"},{"key":"10.1016\/j.jhep.2020.09.013_bib74","article-title":"Simplification of care for chronic hepatitis C virus infection","author":"Pawlotsky","year":"2020","journal-title":"Semin Liver Dis"},{"issue":"8","key":"10.1016\/j.jhep.2020.09.013_bib75","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1053\/j.gastro.2020.02.027","article-title":"Closing the stable door after the horse has bolted - should we be treating people with immune-tolerant chronic hepatitis B to prevent hepatocellular carcinoma?","volume":"158","author":"Howell","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.09.013_bib76","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1478-4491-8-8","article-title":"A\u00a0systematic review of task- shifting for HIV treatment and care in Africa","volume":"8","author":"Callaghan","year":"2010","journal-title":"Hum Resour Health"},{"issue":"1","key":"10.1016\/j.jhep.2020.09.013_bib77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2471\/BLT.16.183772","article-title":"Controlling hepatitis C in Rwanda: a framework for\u00a0a\u00a0national response","volume":"96","author":"Mbituyumuremyi","year":"2018","journal-title":"Bull World Health Organ"},{"issue":"4","key":"10.1016\/j.jhep.2020.09.013_bib78","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.2196\/publichealth.7370","article-title":"Viral hepatitis strategic Information to achieve elimination by 2030: key elements for HIV program Managers","volume":"3","author":"Hutin","year":"2017","journal-title":"JMIR Public Health Surveill"},{"key":"10.1016\/j.jhep.2020.09.013_bib93","series-title":"Task Shifting: Rational Redistribution of Tasks Among Health Workforce Teams: Global Recommendations and Guidelines","year":"2008"},{"key":"10.1016\/j.jhep.2020.09.013_bib79","series-title":"The Selection and Use of Essential Medicines: Report of the WHO Expert Committee, 2017 (Including the 20th WHO Model List of Essential Medicines and the 6th WHO Model List of Essential Medicines for Children)","year":"2017"},{"key":"10.1016\/j.jhep.2020.09.013_bib80","series-title":"Declaration on the Importance of Civil Society Involvement to Eliminate Hepatitis C","year":"2017"},{"issue":"14","key":"10.1016\/j.jhep.2020.09.013_bib81","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.vaccine.2013.01.020","article-title":"Economic evaluation of universal newborn hepatitis B vaccination in China","volume":"31","author":"Lu","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jhep.2020.09.013_bib82","first-page":"158","article-title":"Impact evaluation of the routine hepatitis B vaccination program of infants in China","volume":"41","author":"Sun","year":"2018","journal-title":"J\u00a0Public Health (Oxf)"},{"issue":"9","key":"10.1016\/j.jhep.2020.09.013_bib83","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41575-018-0041-6","article-title":"The hepatitis B epidemic and the urgent need for cure preparedness","volume":"15","author":"Lazarus","year":"2018","journal-title":"Nat Revs Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2020.09.013_bib84","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrgastro.2016.7","article-title":"Global strategies are required to cure and eliminate HBV infection","volume":"13","author":"Revill","year":"2016","journal-title":"Nat Revs Gastro Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820336254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820336254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:41:50Z","timestamp":1759174910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820336254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0168827820336254"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.09.013","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A global investment framework for the elimination of hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}